

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN TREBANANIB
 PRONUNCIATION tre ban' a nib
 THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAME

1. Immunoglobulin G1 (synthetic human Fc domain fragment) fusion protein with angiopoietin 1/angiopoietin 2-binding peptide (synthetic)
2. L-methionyl-human immunoglobulin G1 Fc region {(6-15)-H-CH2-CH3 of IGHG1*03} fusion protein with pentaglycyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-glutamyl-L-glutamyl-L-cysteinyl-L-glutamyl-L-tryptophyl-L-aspartyl-L-prolyl-L-tryptophyl-L-threonyl-L-cysteinyl-L-glutamyl-L-histidyl-L-methionylbis(glycyl-L-seryl)-L-alanyl-L-threonylglycylbis(glycyl-L-seryl)-L-threonyl-L-alanyl-L-seryl-L-serylbis(glycyl-L-seryl)-L-alanyl-L-threonyl-L-histidyl-L-glutaminyl-L-glutamyl-L-glutamyl-L-cysteinyl-L-glutamyl-L-tryptophyl-L-aspartyl-L-prolyl-L-tryptophyl-L-threonyl-L-cysteinyl-L-glutamyl-L-histidyl-L-methionyl-L-leucyl-L-glutamic acid, dimer (7-7':10-10')-bisdisulfide
3. Peptibody, anti-(human angiopoietin-2/angiopoietin-1)(synthetic clone 2xCon4 (C))

STRUCTURAL FORMULA

Monomer

MDKTHTCPPC	PAPELLGGPS	VFLFPPKPKD	TLMISRTPEV	TCVVVDVSHE	50
DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	YRVVSVLTVL	HQDWLNGKEY	100
KCKVSNKALP	APIEKTISKA	KGQPREPQVY	TLPPSRDEL	KNQVSLTCLV	150
KGFYPSDIAV	EWESNGQPEN	NYKTTTPVLD	SDGSFFLYSK	LTVDKSRWQQ	200
GNVFSCSVMH	EALHNHYTQK	SLSLSPGKGG	GGGAQQEECE	WDPWTCEHMG	250
SGSATGGSGS	TASSGSGSAT	HQEECEWDPW	TCEHMLE		287

Disulfide bridges location

7-7'	10-10'	42-102	42'-102'	148-206
148'-206'	239-246	239'-246'	275-282	275'-282'

MOLECULAR FORMULA $C_{2794}H_{4248}N_{752}O_{886}S_{30}$

MOLECULAR WEIGHT 63.511 kDa

TRADEMARK None as yet

SPONSOR Amgen Inc.

CODE DESIGNATION AMG 386

CAS REGISTRY NUMBER 894356-79-7

NOTE: This statement supersedes adopted name *tovasanib* (N09/92). The adoption of *tovasanib* is hereby rescinded.